Pluristem Therapeutics (PSTI) – Company Press Releases
-
Independence Realty Trust Appoints Craig Macnab to its Board of Directors
-
Pluri CEO Issues Shareholder Update
-
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
-
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
-
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
-
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
-
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
-
Pluristem CEO Issues Shareholder Update
-
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
-
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
-
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
-
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
-
Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform
-
Investor Summit Group Provides Update on Upcoming Q4 Virtual Summit
-
Pluristem CEO Issues Shareholder Update
-
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
-
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
-
Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
-
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
-
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
-
Pluristem Announces Uplisting to the Nasdaq Global Market®
-
Pluristem Announces Appointments of Two Directors to Board
-
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico
-
Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public Storage
-
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
-
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
-
World Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering Committee
-
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
-
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
-
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
-
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
-
Pluristem CEO Issues Shareholder Update
-
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
-
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
-
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
-
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
-
Pluristem CEO Issues Shareholder Update on Clinical Programs
-
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
-
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
-
Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
-
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
-
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
-
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
-
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
-
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020
-
Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies
-
Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
-
Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
-
Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use
-
Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity
Back to PSTI Stock Lookup
